This is an immensely exciting time in the study of hematologic malignancies, marked by tremendous progress in basic, translational, and clinical research. To highlight just a few major advances, engineered T-cell treatments and other immunotherapies, along with targeted therapies, represent definitive progress in the clinical realm.
Ultimately, say officials from both Guardant and Foundation Medicine, the goal is to look to the blood not only as a guide for which drugs to use for which patients, but to screen for cancer at even earlier stages, before it’s diagnosed.
Watch as two-time cancer survivor Kierran, shares his story - how he stayed positive and what stem cell transplantation has to do with why he's still here today.
Suddenly, I could see my previous life – of pointless anxieties, petty rivalries and overthinking – for what it was.
Gemini uses casual AI to reconstruct an individual patient and to stimulate how the disease progresses through each patient’s body, and which types of therapies might treat the disease.
When cancer occurs in the blood, it’s usually the result of an abnormal and excessive reproduction of white blood cells. Blood cancers account for about 10 percent of all diagnosed cancers in the U.S. each year. Blood cancers (including leukemia, lymphoma and myeloma) are more common in men than women. Childhood leukemia accounts for about 25 percent of all cancers in children.
Blood cancers occur when there is an uncontrolled growth of blood cells, which can infiltrate tissues and cause disease. The main types of blood cancer are leukaemia, lymphoma and myeloma.
Hematological malignancies have long been testing grounds for leading-edge therapies, but innovation has accelerated in recent years. Many more advances could be on the way.
There are no effective screening tests for the early detection of blood cancers.
Blood Cancer Discovery publishes high-quality Research Articles and Briefs representing major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. T
We're a community dedicated to beating blood cancer by funding research and supporting those affected. Since 1960, we've invested over £500 million in blood cancer research, transforming treatments and saving lives.
Anthony Nolan, saving the lives of people with blood cancer.
DKMS is an international not for profit organization dedicated to the fight against blood cancer and blood disorders by: creating awareness; recruiting bone marrow donors to provide a second chance at life; raising funds to match donor registration costs; supporting the improvement of therapies through research; and supporting patients from day one of their diagnoses.
The three main types of blood and bone marrow cancer are leukemia, lymphoma and myeloma:
In most blood cancers, the normal blood cell development process is interrupted by uncontrolled growth of an abnormal type of blood cell. These abnormal blood cells, or cancerous cells, prevent your blood from performing many of its functions, like fighting off infections or preventing serious bleeding.